Alpha Cognition Inc. Reports Significant Revenue Growth and Increased Operating Expenses for Q3 2025

Alpha Cognition Inc. reported its financial results for the third quarter and the nine months ended September 30, 2025, revealing significant revenue growth and increased operating expenses. The company generated total revenue of $2.84 million for the third quarter, a substantial increase from zero revenue in the same period last year. For the nine months ended September 30, 2025, total revenue reached $7.43 million, driven by product sales and licensing agreements. The company’s product sales amounted to $4.26 million for the nine-month period, while licensing revenue contributed $3.17 million.

In terms of expenses, Alpha Cognition's total operating expenses for the third quarter were $8.15 million, up from $2.49 million in the prior year, marking a 228% increase. This rise was primarily attributed to a significant increase in selling, general, and administrative expenses, which surged to $6.95 million from $1.47 million year-over-year. Research and development expenses also decreased to $573,592 from $996,029, reflecting a strategic shift following the FDA approval of its product ZUNVEYL in July 2024. The net loss for the third quarter was $1.32 million, a 29% improvement compared to a loss of $1.86 million in the same quarter of 2024.

Operationally, Alpha Cognition has made strides in expanding its product offerings and market presence. The company launched ZUNVEYL, a treatment for mild-to-moderate Alzheimer’s disease, in March 2025, and has focused on establishing partnerships with long-term care facilities. As of September 30, 2025, the company reported an accumulated deficit of $90.1 million and had cash and cash equivalents of $35.46 million, down from $48.56 million at the end of 2024. The decrease in cash is attributed to increased operational costs and investments in commercial activities.

The company has also engaged in strategic financing activities, including a public offering completed on October 2, 2025, which raised approximately $35 million. This offering included the issuance of common shares and pre-funded warrants. Additionally, Alpha Cognition entered into an At the Market Offering Agreement in August 2025, allowing it to sell up to $75 million in common shares over time. The company anticipates that these funds will support its ongoing commercialization efforts and research and development activities.

Looking ahead, Alpha Cognition plans to continue leveraging its cash reserves to fund operations and further develop its product pipeline. The company remains focused on the commercialization of ZUNVEYL and exploring additional financing options to support its growth strategy. However, management acknowledges the risks associated with obtaining timely financing and the potential impact on its operational plans.